Point Vision changes hands.
The company, which has established itself in ten years as the leader in ophthalmological centers, welcomes two new shareholders to its capital.
The Ares Management Corporation fund becomes the majority shareholder, succeeding Abenex.
Bpifrance is also entering the capital.
Point Vision is sold at a high price, around 250 million euros, according to our information.
Read also
Point Vision is testing an ophthalmological teleconsultation center
The new shareholders won over the Adagio fund and the Elsan group of clinics, attracted by significant industrial synergies, which were among the candidates. The three founders of Point Vision have decided to go back to the pot, alongside many of the company's employees.
The objective of this new round table is to support the company in a new stage of its growth.
The group, which takes care of 1.2 million patients per year in its 48 centers, is opening a
“new chapter”
in its history.
“
Our medical project is enriched with the advent of teleconsultation in advanced positions in ophthalmology in small towns and the development of“ subspecialties ”such as surgery, medical retina, contactology or even facial aesthetics
, explains François Pelen, ophthalmologist, one of the three founders of Point Vision.
This requires investments to match our ambitions, in the service of our fellow citizens.
"
Read also
Opticians are finally seeing their customers return
Point Vision's model consists of relieving doctors of administrative tasks and using orthoptists as backup.
This allows centers to take more patients, reduce the time it takes to get appointments and reduce waiting times.
"Point Vision is an innovative company serving patients, it responds to a public health mission and indirectly contributes to reducing health insurance costs by treating people on time"
, enthuses Anne-Sophie Hérelle, director. development capital at Bpifrance.
Point Vision intends to complete its territorial network.
This should lead it to pursue external growth operations.
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/56XAYHM37FH45ARX6TUXG63UWQ.jpg)
